Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law FDA takes first step in possible reversal of ban on some peptides The Washington Post Regulatory Updates on Compounded Peptides New Drug Loft and VLS Pharmacy BPC 157 and the Difference Between an Evidence Gap and a Cover Up: What the entire human evidence base actually looks like, and the questions to ask next. WellFounded Founders Health & The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions